Topical research formulations commonly reference GHK-Cu concentrations in the range of 0.05% to 2%, with research formulations frequently using 1-2% for skin regeneration research and lower concentrations for sensitive-area research
The authors themselves described it as a small preliminary study.[15] A 2025 pilot report described intravenous administration to two healthy adults at doses up to 20 mg, with no measurable changes in cardiac, hepatic, renal or thyroid biomarkers and no reported adverse effects.[16] Two individuals cannot characterise uncommon reactions, immunogenicity, long-term toxicity, reproductive safety or oncological risk
Peptides degrade rapidly and dont produce long-lasting metabolites, making them nearly invisible in standard immunoassay urine tests
Not intended for human or veterinary use, consumption, administration, or diagnostic purposes